GSK Q3 2026 earnings show 5% sales growth, specialty medicines up 15% and guidance reaffirmed

GlaxoSmithKline reported third‑quarter 2026 sales of £8.9 billion, a 5% increase year‑over‑year, and core earnings per share rose 1%. Specialty medicines drove a 15% sales rise, while cash generation hit £7.4 billion year‑to‑date, supporting a 17 pence per share dividend. The company reaffirmed its full‑year 2026 guidance and highlighted the launch of 18 Phase III trials as part of its accelerated pipeline program.

The reaffirmed guidance signals that GSK expects to meet the upper half of its sales and profit targets for 2026, which may sustain investor confidence. Strong cash generation underpins the announced dividend, providing immediate income to shareholders.

  • 1Third‑quarter 2026 sales were £8.9 billion, up 5% year‑over‑year.
  • 2Core earnings per share increased 1% in the quarter.
  • 3Specialty medicines sales grew 15% in Q3.
  • 4Cash generation reached £7.4 billion year‑to‑date.
  • 5The board declared a third‑quarter dividend of 17 pence per share.
  • 6GSK reaffirmed its full‑year 2026 guidance on sales and profit margins.

Sources